BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) and PEI (Paul-Ehrlich-Institut) provided supplementary recommendations to the guideline on management of clinical trials during COVID-19 released by the European authorities on 20th March 2020.
Key points of BfArM and PEI recommendations on remote source data verification procedures (rSDV) in Germany:
- rSDV should only be considered in exceptional cases and only to the extent necessary.
- rSDV requires written approval by the investigator and the site. In Germany approval by the regulatory authority and ethics committee is required as well. In the application the planned rSDV approach needs to be described, starting with a study-specific risk assessment. This risk assessment can be part of the study protocol (Quality Control and Quality Assurance section) or an appendix to the protocol.
- SOPs and study-specific documents (those on risk-based quality management and monitoring) need to be adapted accordingly.
- The method chosen for rSDV (the EMA guidelines lists three options) depends on the infrastructure of the sites. In the application for approval, the sponsor shall list all rSDV methods which may apply because only the ones submitted can obtain approval.
- For each rSDV method, the source document/data made available under rSDV, as well as information on precautions taken to preserve confidentiality of data and privacy of trials subjects must be provided.
- The guidance then lists specific information required for each of the 3 rSDV approaches. It also covers requirements for document management systems and telemedicine. Additional data protection considerations may apply.
For more details, please see the official communication from the Paul-Ehrlich-Institut.
Meditrial can help – Contact us for immediate support
Meditrial has developed rapid workflows to conduct risk assessment, implement rescue plans and execute solutions for ongoing clinical trials:
- Identify patients requiring follow-up
- Conduct investigator and study nurse calls for training to address the situation
- Obtain authorizations for decentralized data collection
- Support to patients for alternative access to needed care
- Prepare procedures and worksheets for remote collection of patient clinical data
- Monitor work instructions and trainings for site support and remote monitoring
- EDC and ePRO solutions to enable study continuity
- Privacy protection measures
Contact Meditrial for immediate assistance in Europe or the US.
Table of Contents
Latest Articles
Practical 510(k) vs PMA vs De Novo FDA Pathway Guide
Practical 510(k) vs PMA vs De Novo guidance for choosing an FDA device pathway based on classification, predicates, risk, and evidence needs
Build a Defensible Clinical Evidence Strategy Under EU MDR
Build a defensible clinical evidence strategy under MDR Annex XIV, from the clinical evaluation plan to PMCF and notified body review.
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
This article provides general information and does not constitute regulatory, legal, clinical, or compliance advice. Requirements and appropriate processes may vary by study, product, jurisdiction, and organization. Medigen Suite functionality should be used in accordance with applicable regulations, study documentation, and internal procedures.
